Bellicum Pharmaceuticals, Inc. - Common Stock BLCM announces its next round of earnings Tuesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.
Earnings and Revenue
Analysts are expecting Bellicum Pharmaceuticals to report a loss of 70 cents per share. Revenue will likely be around $840,000, according to the consensus estimate.
In the same quarter last year, Bellicum Pharmaceuticals reported a loss per share of 74 cents on revenue of $81,000.
Here's how the company's EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.74 | -0.66 | -0.7 | -0.7 |
| EPS Actual | -0.71 | -0.74 | -0.8 | -0.74 |
Stock Performance
Over the last 52-week period, shares of Bellicum Pharmaceuticals have declined 39.03 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Long-term shareholders are already wary of 12-month losses prior to the announcement.
Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The average rating by analysts on Bellicum Pharmaceuticals stock is a Neutral. The validity of this rating has maintained conviction over the past 90 days.
Conference Call
Bellicum Pharmaceuticals Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here: http://bellicum.equisolvewebcast.com/q4-2017
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
